Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-071873
What the release said
Net income was $58.2 million for the three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025.
Collaboration revenue was $83.5 million for the three months ended September 30, 2026, compared to $8.2 million, driven by a $74.1 million cumulative catch-up adjustment.¶2
Net income was $58.2 million for the three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025.¶1
Research and development expenses were $18.8 million and general and administrative expenses were $5.8 million for the three months ended September 30, 2026.¶3¶4
As of September 30, 2026, the Company had $156.2 million in cash, cash equivalents, and marketable securities, providing cash runway into the second half of 2029.¶5
Dose-range finding studies for the oral I&I program are expected to begin in the fourth quarter of 2026, with potential first-in-human studies by the end of 2027.¶6
- Collaboration revenue
- $83.5 million Three months ended September 30, 2026, compared to $8.2 million for the three months ended September 30, 2025¶2
- Net income
- $58.2 million Three months ended September 30, 2026, compared to a net loss of $15.8 million for the three months ended September 30, 2025¶1
- Research and development expenses
- $18.8 million Three months ended September 30, 2026, compared to $20.0 million for the three months ended September 30, 2025¶3
- General and administrative expenses
- $5.8 million Three months ended September 30, 2026, compared to $6.7 million for the three months ended September 30, 2025¶4
- Cash, cash equivalents, and marketable securities
- $156.2 million As of September 30, 2026¶5
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $83.54M | $8.15M | $7.81M | $17.48M |
| Net Income | $58.15M | -$15.85M | -$19.12M | -$14.35M |
| EPS Diluted | $0.80 | -$0.25 | -$0.31 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR